180 related articles for article (PubMed ID: 38557494)
1. Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis.
Steffani M; Geng Y; Pajvani UB; Schwabe RF
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557494
[TBL] [Abstract][Full Text] [Related]
2. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
3. Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
Bendixen SM; Jakobsgaard PR; Hansen D; Hejn KH; Terkelsen MK; Bjerre FA; Thulesen AP; Eriksen NG; Hallenborg P; Geng Y; Dam TV; Larsen FT; Wernberg CW; Vijayathurai J; Scott EAH; Marcher AB; Detlefsen S; Grøntved L; Dimke H; Berdeaux R; de Aguiar Vallim TQ; Olinga P; Lauridsen MM; Krag A; Blagoev B; Ravnskjaer K
J Hepatol; 2024 Mar; 80(3):467-481. PubMed ID: 37972658
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression.
Yan T; Yan N; Xia Y; Sawaswong V; Zhu X; Dias HB; Aibara D; Takahashi S; Hamada K; Saito Y; Li G; Liu H; Yan H; Velenosi TJ; Krausz KW; Huang J; Kimura S; Rotman Y; Qu A; Hao H; Gonzalez FJ
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557493
[TBL] [Abstract][Full Text] [Related]
5. Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).
Wang S; Friedman SL
Sci Transl Med; 2023 Oct; 15(716):eadi0759. PubMed ID: 37792957
[TBL] [Abstract][Full Text] [Related]
6. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
Armandi A; Bugianesi E
Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
[TBL] [Abstract][Full Text] [Related]
7. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis.
Mladenić K; Lenartić M; Marinović S; Polić B; Wensveen FM
Eur J Immunol; 2024 Apr; 54(4):e2149641. PubMed ID: 38314819
[TBL] [Abstract][Full Text] [Related]
8. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
9. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
10. Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review.
Castagneto-Gissey L; Bornstein SR; Mingrone G
Metabolism; 2024 Feb; 151():155721. PubMed ID: 37923007
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte and stellate cell deletion of liver fatty acid binding protein reveals distinct roles in fibrogenic injury.
Newberry EP; Xie Y; Lodeiro C; Solis R; Moritz W; Kennedy S; Barron L; Onufer E; Alpini G; Zhou T; Blaner WS; Chen A; Davidson NO
FASEB J; 2019 Mar; 33(3):4610-4625. PubMed ID: 30576225
[TBL] [Abstract][Full Text] [Related]
12. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
13. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
[TBL] [Abstract][Full Text] [Related]
14. RASSF4 attenuates metabolic dysfunction-associated steatotic liver disease progression via Hippo signaling and suppresses hepatocarcinogenesis.
Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
Cell Mol Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38697356
[TBL] [Abstract][Full Text] [Related]
15. Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD.
Schilcher K; Dayoub R; Kubitza M; Riepl J; Klein K; Buechler C; Melter M; Weiss TS
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686029
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38367743
[TBL] [Abstract][Full Text] [Related]
17. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Subramanian P; Hampe J; Tacke F; Chavakis T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
[TBL] [Abstract][Full Text] [Related]
18. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease.
Yashaswini CN; Qin T; Bhattacharya D; Amor C; Lowe S; Lujambio A; Wang S; Friedman SL
J Hepatol; 2024 Mar; ():. PubMed ID: 38508241
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
Gaul S; Leszczynska A; Alegre F; Kaufmann B; Johnson CD; Adams LA; Wree A; Damm G; Seehofer D; Calvente CJ; Povero D; Kisseleva T; Eguchi A; McGeough MD; Hoffman HM; Pelegrin P; Laufs U; Feldstein AE
J Hepatol; 2021 Jan; 74(1):156-167. PubMed ID: 32763266
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.
Piras IS; DiStefano JK
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38565287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
